论文部分内容阅读
[目的]探讨化疗联合三维适行放疗治疗进展期胃癌根治术患者的临床疗效和安全性。[方法]85例行胃癌根治术的进展期胃癌随机分为治疗组(42例)和对照组(43例)。治疗组采用化疗联合三维适行放疗治疗,对照组采用化疗治疗。疗程结束后评价近期疗效、观察毒副反应,随访1年评价客观疗效和生存率。[结果]治疗组近期疗效有效率为81.0%,高于对照组(57.1%),两组相比较差异有统计学意义(P﹤0.05);治疗组1年生存率和中位疾病进展时间显著高于对照组,两组相比较差异均有统计学意义(P﹤0.05);两组毒副反应比较差异均有统计学意义(P﹤0.05)。[结论]联合三维适行放疗治疗进展期胃癌根治术患者临床疗效肯定,毒副反应小,值得临床推广。
[Objective] To investigate the clinical efficacy and safety of chemotherapy combined with three-dimensional adaptive radiotherapy in patients with advanced gastric cancer undergoing radical operation. [Method] Eighty-five advanced gastric cancer patients with radical gastrectomy were randomly divided into treatment group (42 cases) and control group (43 cases). The treatment group with chemotherapy combined with three-dimensional appropriate radiotherapy, the control group with chemotherapy. After the course of treatment evaluation of the recent curative effect, observe the side effects, follow-up 1 year evaluation objective curative effect and survival rate. [Results] The effective rate of treatment in the treatment group was 81.0%, higher than that in the control group (57.1%), the difference was statistically significant (P <0.05). The 1-year survival rate and median disease progression time were significant Higher than the control group, the difference between the two groups was statistically significant (P <0.05); two groups were statistically significant differences in side effects (P <0.05). [Conclusion] Combined three-dimensional proper radiotherapy for advanced radical gastrectomy patients with definite clinical efficacy, side effects, worthy of clinical promotion.